South Korean Scientists Link High Blood Pressure to Accelerated Joint Cartilage Damage in Osteoarthritis

How Hypertension Influences Osteoarthritis Progression

According to НВ — Техно: A team of international researchers from Chonnam National University in South Korea has uncovered that elevated blood pressure worsens joint cartilage deterioration in osteoarthritis by activating the AVPR1A receptor through the hormone arginine vasopressin. Published in the journal Science on October 2, the study highlights a significant connection between hypertension and the advancement of osteoarthritis, particularly among women and patients with severe knee injuries.

Examining health data from 36,820 individuals aged 45 and older, the researchers found that high blood pressure contributes to cartilage breakdown in osteoarthritis patients. Those with chronic hypertension exhibited increased levels of arginine vasopressin (AVP), while the AVPR1A receptor-rarely present in healthy cartilage-was found to rise with age or following joint trauma. Laboratory tests on mice modeling osteoarthritis confirmed that hypertension intensifies cartilage loss in damaged joints. Notably, elevated blood pressure did not cause harm to healthy joints lacking prior injury or aging-related changes.

Potential for New Osteoarthritis Treatments

Blocking the AVPR1A receptor or genetically eliminating it in mice significantly reduced joint damage, opening the door to innovative drug development targeting the AVP-AVPR1A pathway. With nearly 600 million people worldwide affected by osteoarthritis and treatment options largely unchanged for over 20 years, this discovery offers promising avenues for therapeutic advances. The findings also shed light on how obesity and hypertension may exacerbate musculoskeletal disorders.

Understanding the molecular link between high blood pressure and osteoarthritis progression is a critical step toward creating novel treatment strategies for this widespread condition. As the number of osteoarthritis patients continues to climb globally, breakthroughs like this emphasize the urgent need for improved therapies. Insights into arginine vasopressin’s role present exciting possibilities for future research and drug development aimed at reducing the damaging effects of hypertension on joint health.

As researchers delve deeper into the links between hypertension and joint health, it becomes increasingly clear that understanding conditions like primary aldosteronism is crucial. This condition, which can affect up to 20% of patients with hypertension, may play a significant role in cardiovascular and musculoskeletal health. Insights from a recent study on a portable device for diagnosing primary aldosteronism highlight the need for comprehensive approaches to managing high blood pressure and related disorders.